Morgan Stanley Galmed Pharmaceuticals Ltd. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.4 - $0.9 $9,408 - $21,168	23,521 Added 13.01%	204,245 $87,000
Q4 2022 Feb 14, 2023	SELL	$0.29 - $0.59 $2,579 - $5,248	-8,896 Reduced 4.69%	180,724 $90,000
Q3 2022 Nov 14, 2022	SELL	$0.35 - $0.65 $2,127 - $3,951	-6,079 Reduced 3.11%	189,620 $59,000
Q2 2022 Oct 27, 2022	BUY	$0.44 - $1.77 $13,375 - $53,806	30,399 Added 18.39%	195,699 $127,000
Q2 2022 Aug 15, 2022	BUY	$0.44 - $1.77 $13,375 - $53,806	30,399 Added 18.39%	195,699 $127,000

Q1 2022 Oct 27, 2022	SELL	$1.23 - $2.07 $37,390 - $62,925	-30,399 Reduced 15.53%	165,300 $263,000
Q1 2022 May 13, 2022	BUY	$1.23 - $2.07 $5,535 - $9,315	4,500 Added 2.8%	165,300 $263,000
Q4 2021 Feb 14, 2022	SELL	$1.75 - $3.03 $6,475 - $11,211	-3,700 Reduced 2.25%	160,800 $293,000
Q3 2021 Nov 15, 2021	BUY	$2.41 - $3.33 $396,445 - $547,785	164,500 New	164,500 $459,000

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $7.02M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.